Introduction were generated in this study. Their construction is described below. The expression vector p[Met 1 ]-pGH(1-46)VNFAHYOver recent years, fusion protein technology has become a powerful tool in biochemistry. Today a large number of fusion IGF-II was generated by ligating the HpaI-HindIII fragment from a VNFAHY-IGF-II pTZ18 vector (Francis et al. 1993 ) partners are available to aid the isolation and purification of heterologous proteins from Escherichia coli (Nilsson et al., into a similarly treated p[Met 1 ]-pGH(1-46)VN expression vector (King et al. 1992) . The construct p[Met 1 ]-pGH . However, to generate authentic product the fusion partner must be removed. Downstream processing of the fusion 46)-VNPASG 4 AFAHY-IGF-II was generated by introducing, via site-directed mutagenesis (Mutagene kit, BioRad, Richprotein will often involve chemical or enzymatic removal of the fusion partner (Carter, 1990; Nilsson et al., 1992) . mond, CA, USA), DNA encoding an eight amino acid spacer into the VNFAHY-IGF-II pTZ18 vector using the Consequently, to obtain a high yield of the recombinant product, it is important to design the fusion protein for effective oligonucleotide 5ЈTCGGTTAACCCGGCTAGCGGTGGTG-GTGGCGCCTTCGCCCATTATGCT3Ј. The new construct removal of the fusion partner.
In this study, the 67 amino acid residue insulin-like growth was subsequently cloned into the HpaI and HindIII digested expression vector. When expressed this construct generates factor II (IGF-II) (Rinderknecht and Humbel, 1978) was produced in E.coli at high levels with a 46 amino acid residue FP-B.
An EcoRI-HpaI fragment containing DNA encoding [Met 1 ]-N-terminal extension derived from methionyl porcine growth hormone ([Met 1 ]-pGH) (King et al., 1992) . To facilitate pGH(1-46)-VN was subcloned into pTZ18 for two further mutagenesis reactions. The first event replaced the two codons enzymatic release of IGF-II, an H64A subtilisin (Carter et al., 1989) recognition motif (Phe-Ala-His-Tyr) has been introduced for the histidine residues at positions 20 and 22 in [Met 1 ]-pGH (1-46) with codons for alanine and glutamine residues, respecbetween the moieties. IGF-II has previously been expressed in E.coli with a 13 amino acid N-terminal extension derived tively, using the oligonucleotide 5ЈGTGCTCCGGGCCCA-GGCCCTGCAGCAACTGGCTGC-C3Ј. The mutation was from [Met 1 ]-pGH (Francis et al., 1993 
FP-D. These expression vector constructs were transformed
The amino acid residues are represented by single-letter amino acid into E.coli JM101 (lac q ) and selected on minimal agar conabbreviations. The H64A subtilisin recognition motif, FAHY, is represented as a solid black box.
taining 29 µM ampicillin.
Expression and isolation of fusion proteins
microbore C 4 column (2.1ϫ100 mm; Brownlee Laboratories, Expression of each construct was achieved by inoculating 1 Santa Clara, CA, USA). Determination of IGF-II activity was l of 2YT supplemented with 58 µM ampicillin with 20 ml performed using an L-6 myoblast protein synthesis assay as of an overnight culture. Cells, grown in shaker flasks at 37°C, described by Francis et al. (1986) . IGF-II liberated by were induced at an A 600 of 0.8 with 1 mM isopropyl-β-Ddigestion of refolded FPs was quantified in two steps. First galactoside for 6 h. Inclusion bodies were harvested as the areas of peaks on the chromatograms were analysed. In described previously (King et al., 1992) and solubilized in addition, the products present in the active fractions from 8 M urea containing 0.1 M Tris, 40 mM glycine, 40 mM RP-HPLC were analysed on high-density polyacrylamide DTT and 5 mM ZnCl 2 , pH 9.0 (Upton et al., 1992) . The gels under reducing conditions. Fractions with IGF-II also fusion proteins were purified by gel filtration (Superdex-75, contained cleaved fusion partners. Laser densitometry, using 26ϫ600 mm; Pharmacia, Uppsala, Sweden) using the buffer a Molecular Dynamics (Sunnyvale, CA, USA) Model 300A described above but containing 1.6 mM DTT. The appropriate densitometer with ImageQuant software, was performed on fractions containing the fusion protein were pooled and the SDS-PAGE gels to determine the proportion of material desalted by dialysis against 10 mM HCl or by RP-HPLC, in the active fractions which was IGF-II, taking into considerabefore being concentrated using an ultrafiltration cell tion the effect of molecular weight on Coomassie Blue (Amicon, Beverly MA, USA) and then lyophilized. The staining. Subsequently, the relative amounts of IGF-II in each fusion proteins were reconstituted in the solubilization buffer case were estimated by combining the data from laser described above before dilution to the appropriate concentradensitometry and peak areas from RP-HPLC. tion for characterization. N-Terminal sequencing was performed by Edman degradaRefolding and cleavage of the fusion proteins tion with a Model 470A gas-phase sequencer (Applied BiosysThe IGF-II fusion proteins were diluted in refolding buffer tems, Foster City, CA, USA) by the methods of Hunkapiller (4 M urea, 0.1 M Tris, 40 mM glycine, 1 mM cystine, 1 mM et al. (1983) . The molecular weight of IGF-II was determined DTT and 0.5 mM EDTA, pH 9.0) to a concentration of 0.5 by analysis on an API-300 electrospray mass spectrometer mg/ml. The refolding solution was then dialysed, in tubing (Perkin-Elmer SCIEX, Melbourne, Australia). with a molecular weight cut-off of 3500, overnight at room temperature against the above buffer without DTT. The Results refolding was terminated by acidification to pH 3 with 1 M Fusion protein design, expression and purification acetic acid.
Fusion proteins with different spacer peptides designed to The fusion proteins were cleaved essentially as described improve enzymatic liberation of authentic IGF-II from their by Francis et al. (1993) at a protein concentration of 0.25 fusion partners by H64A subtilisin are described in Figure 1 . mg/ml in 2 M urea, 100 mM Tris, 5 mM CaCl 2 and 1 mM Two fusion proteins, FP-C and FP-D, included a replacement DTT, pH 8.0, except where refolded fusion proteins were in the fusion partner to remove a competing enzyme recogniused as substrate, when DTT was removed from the digestion tion site (Figure 1 were used for the expression of the fusion proteins designated FP-A, FP-B, FP-C and FP-D, respectively. Following solubilAll proteins were analysed by electrophoresis using Pharmacia PhastSystem high-density gels. Quantitative determination of ization from inclusion bodies and purification by gel filtration and RP-HPLC, the fusion proteins were shown to be at least protein concentration was performed by RP-HPLC on a the other of~4.5 kDa (Figure 2A ). The 7.4 kDa product, which comigrated with an IGF-II standard on the gel, had an N-terminal sequence identical with IGF-II. The 4.5 kDa product most likely is the result of cleavage of the fusion partner between glutamate 19 and histidine 20 (described by Upton et al., 1995) , where the histidine residue is utilized at the P1Ј position (Carter et al., 1989) . This cleavage event yields the product pGH(20-46)VNPASG 4 AFAHY (expected mass of the peptide 4414). Therefore, in order to remove the competing recognition motif from the fusion partner, the replacements H20A and H22Q were introduced in the fusion peptide. Two additional fusion proteins with different length spacer peptides were then also produced (FP-C and FP-D, Figure 1 ). H64A 
Cleavage of refolded IGF-II fusion proteins (---).
The enzymatic removal of the fusion partner was also investigated when refolded fusion protein was used as a substrate. 90% pure, as determined by N-terminal sequencing. Typically,
The products of the digestion were separated by RP-HPLC 1 l of growth medium yielded 100 mg wet weight of inclusion and the fractions containing biologically active IGF-II were bodies, producing 5 mg of purified peptide.
identified using an L6 myoblast protein synthesis assay. Quant-
Cleavage of IGF-II fusion proteins prior to refolding
itation of the digestion is described in Materials and methods and essentially involved determination of peak areas on the The fusion partners were designed to be removed from the IGF-II moiety using H64A subtilisin digestion. It was RP-HPLC traces and quantitation of purity by SDS-PAGE. All IGF-II fusion proteins were cleaved by H64A subtilisin investigated whether a spacer N-terminal to the recognition motif could improve the cleavage of fusion proteins prior to and the modified fusion proteins were clearly better substrates than the parent construct. The proportion of uncleaved fusion refolding. The cleavage reactions were followed by reducing SDS-PAGE and N-terminal sequencing. No digestion was proteins (eluting between 16 and 22 min in RP-HPLC) is expressed as a percentage of the total amount of protein in observed when the parent fusion protein, FP-A, was treated with H64A subtilisin (Figure 2A ). The 13.5 kDa product, Table I . The two fusion proteins with the H20A, H22Q replacements were clearly superior as all of the starting material which corresponds to the full length fusion protein, remained intact even after 24 h of enzymatic treatment (Figure 2A) . In was digested after 24 h. In the cases of FP-C and -D, material eluted at a retention time in RP-HPLC later than the initial contrast FP-B was a more favourable substrate, being digested to completion within 5 h. uncleaved refolded fusion protein (Ͼ22 min). This was not regarded as uncleaved material but products of the cleavage FP-B was completely digested by H64A subtilisin, yielding two products after only 5 h of digestion, one of 7.4 kDa and reaction. The parent construct FP-A was the least desirable substrate as the enzyme with 15.8% of FP-A remaining of the fusion proteins to obtain native IGF-II required oxidative refolding and enzymatic removal of the fusion partner using uncleaved after 24 h protease treatment ( Figure 2B and summarized in Table I ). The three modified fusion proteins H64A subtilisin. Site-specific removal of the fusion partner to produce unmodified IGF-II was technically difficult, most were better substrates in this respect, with FP-C and -D being the most desirable substrates with essentially all of the starting likely due to the fusion partner forming a secondary structure which sterically hinders the action of the enzyme (Carter, material being cleaved (Table I) . FP-B was also an improved substrate compared with FP-A, with only 6.4% of the products 1990). In addition, a recognition motif in the fusion partner competed effectively with the engineered motif for cleavage remaining undigested ( Figure 2B) .
The enzymatic liberation of IGF-II from the fusion proteins by the enzyme (Upton et al., 1995) . The introduction of unstructured, flexible spacer peptides into the fusion proteins was next assessed. For FP-A the amount of IGF-II produced corresponded to 5% of the total material eluted in RP-HPLC.
described in this paper improved the enzymatic removal of the fusion partner from unfolded and refolded substrates. The The products in the fractions that co-eluted with an IGF-II standard were determined to have IGF-II activity in the fusion protein with a 16 amino acid linker was the most desirable substrate for cleavage. Furthermore, by mutating the biological activity assay and the correct mass when analysed by reducing SDS-PAGE. Introduction of a spacer peptide into competing recognition motif in the fusion partner, all substrate was cleaved and the rate of cleavage was further enhanced. FP-B improved the enzymatic liberation of IGF-II from the fusion protein as 7.4% of the material in the reaction eluted
Interdomain spacer regions or linkers in native proteins have been shown to be important structural elements. These regions, in the active fraction after 24 h of digestion and was indeed IGF-II. Samples of the digestion were taken after 1 and 5 h rich in glycine, serine, alanine and threonine residues, are usually hydrophilic and flexible (Argos, 1990) . Deletion of treatment times but no IGF-II was detected by RP-HPLC analysis, suggesting that the action of the protease with these linkers in cellulose-binding protein (Srisodsuk et al., 1993) , heat shock transcription factor (Flick et al., 1994) and multisubstrates is not rapid (data not shown). These results show that the presence of the spacer peptide made the fusion protein functional CAD protein (Guy and Evans, 1994) either abolishes or almost eliminates the biological functioning of these proa more favourable substrate for H64A subtilisin. A 1.5-fold increase in the quantity of active IGF-II released from the teins, suggesting that these regions are required for the formation of correct protein conformation. Spacer peptides have also fusion protein was observed by the introduction of the spacer.
Finally when the refolded FP-C and FP-D were digested been introduced into a variety of recombinant proteins to create single-chain antibodies (Bird et al., 1988; Huston et al., with H64A and analysed, 8.8 and 10 .3% of the material eluted in RP-HPLC was IGF-II, respectively. Therefore, the amount 1988; Pantoliano et al., 1991) , fusions of two or more subunits (Brinkmann et al., 1992; Liang et al., 1993; Predki and Regan, of IGF-II liberated from FP-C was similar to that from FP-B, whereas an increase in spacer length (FP-D) resulted in further 1995) and circulatory permuted proteins such as T4 lysozyme (Zhang et al., 1993) . improvement of cleavage yields (data summarized in Table I ). In contrast to both FP-A and FP-B, cleavage of the fusion
The improved accessibility of H64A subtilisin to its cleavage site in the IGF-II fusion protein by utilizing spacer peptides protein was detected by RP-HPLC after only 5 h when FP-C was used as a substrate. These results suggest that although is comparable to other studies in which the removal of an Nterminal fusion partner was facilitated using thrombin (Guan the final yield of active IGF-II from FP-C was not improved above that from FP-B by the removal of the competing H64A
and Dixon, 1991) and Factor X a (Rodríguez and Carrasco, 1995) . Glycine-rich spacers, introduced C-terminally of the subtilisin cleavage site, the rate of cleavage was improved. Comparing the RP-HPLC traces and SDS-PAGE analysis of cleavage site, improved the removal of the N-terminal extensions. This approach does, however, yield a product with a the fractions for all digestions showed that a 2.2 kDa product corresponding to [Met 1 ]pGH(1-19), which eluted at 9 min in modified N-terminus. The present study showed that a glycinerich spacer introduced N-terminally to the cleavage motif can the gradient in chromatograms for FP-A and -B, was not present in digestions of FP-C and -D ( Figure 2B ). This also be used to improve the cleavage by H64A subtilisin, presumably by exposing the cleavage site and thus yielding further proves that the H20A, H22Q replacements remove the competing protease site in the fusion partner.
products with correct amino termini.
In conclusion, spacer peptides were introduced N-terminally In order to characterize the IGF-II released after refolding and cleavage of FP-C, the material in the biologically active to an H64A subtilisin recognition motif in a high-level expression system for the production of IGF-II fusion proteins. The fractions from the RP-HPLC was pooled, lyophilized and subjected to mass spectrometry. The material had a mass of fusion proteins containing spacers had superior properties as site-specific cleavage was improved, while retaining the native 7470 (expected mass ϭ 7471), thus confirming the production of IGF-II.
N-termini of the product. In summary, introduction of spacer peptides of eight amino acids in length between the fusion partner and IGF-II improved
